← All trials
NCT05057949
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 21, 2021
- Primary completion
- Mar 21, 2022
- Completion date
- Jun 21, 2022
- First posted
- Sep 27, 2021
- Last posted
- Oct 29, 2021
- Enrollment
- 32
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Sunshine Lake Pharma Co., Ltd.Lead sponsor
- Jinlin UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.